Guardian Capital LP raised its holdings in shares of Colgate-Palmolive (NYSE:CL) by 6.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,953 shares of the company’s stock after purchasing an additional 5,271 shares during the period. Guardian Capital LP’s holdings in Colgate-Palmolive were worth $6,189,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CL. Jacobi Capital Management LLC grew its holdings in shares of Colgate-Palmolive by 125.5% during the 3rd quarter. Jacobi Capital Management LLC now owns 1,443 shares of the company’s stock worth $104,000 after acquiring an additional 803 shares during the period. Krilogy Financial LLC grew its holdings in shares of Colgate-Palmolive by 23.0% during the 2nd quarter. Krilogy Financial LLC now owns 1,547 shares of the company’s stock worth $115,000 after acquiring an additional 289 shares during the period. Captrust Financial Advisors purchased a new position in shares of Colgate-Palmolive during the 2nd quarter worth approximately $122,000. AlphaMark Advisors LLC grew its holdings in shares of Colgate-Palmolive by 1.5% during the 2nd quarter. AlphaMark Advisors LLC now owns 1,698 shares of the company’s stock worth $126,000 after acquiring an additional 25 shares during the period. Finally, Bruderman Asset Management LLC purchased a new position in shares of Colgate-Palmolive during the 2nd quarter worth approximately $126,000. 72.86% of the stock is owned by institutional investors and hedge funds.

Shares of Colgate-Palmolive (CL) opened at $77.50 on Friday. The company has a debt-to-equity ratio of 24.42, a current ratio of 1.23 and a quick ratio of 0.92. The firm has a market capitalization of $68,053.13, a P/E ratio of 27.00, a P/E/G ratio of 3.24 and a beta of 0.80. Colgate-Palmolive has a 52 week low of $63.43 and a 52 week high of $77.91.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, October 27th. The company reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The business had revenue of $3.97 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same period last year, the business posted $0.73 EPS. The company’s revenue was up 2.8% compared to the same quarter last year. analysts forecast that Colgate-Palmolive will post 2.87 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Tuesday, January 23rd will be paid a dividend of $0.40 per share. The ex-dividend date is Monday, January 22nd. This represents a $1.60 annualized dividend and a yield of 2.06%. Colgate-Palmolive’s dividend payout ratio is 61.78%.

In other Colgate-Palmolive news, Director Stephen I. Sadove sold 20,780 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $70.52, for a total transaction of $1,465,405.60. Following the sale, the director now directly owns 36,268 shares in the company, valued at approximately $2,557,619.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Justin Skala sold 126,393 shares of the stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $72.97, for a total value of $9,222,897.21. Following the sale, the chief operating officer now owns 262,361 shares in the company, valued at $19,144,482.17. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 181,950 shares of company stock worth $13,237,385. Company insiders own 1.02% of the company’s stock.

CL has been the topic of a number of research analyst reports. Citigroup reduced their target price on Colgate-Palmolive from $76.00 to $75.00 and set a “neutral” rating on the stock in a report on Thursday, November 2nd. Zacks Investment Research upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $81.00 price target on the stock in a research note on Monday, October 23rd. KeyCorp restated a “hold” rating on shares of Colgate-Palmolive in a research note on Saturday, November 25th. Macquarie upgraded Colgate-Palmolive from a “neutral” rating to an “outperform” rating and set a $81.00 price target on the stock in a research note on Tuesday, December 19th. Finally, SunTrust Banks upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and upped their price target for the stock from $65.00 to $85.00 in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the stock. Colgate-Palmolive has an average rating of “Hold” and a consensus target price of $76.45.

TRADEMARK VIOLATION WARNING: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2018/01/21/colgate-palmolive-cl-holdings-lifted-by-guardian-capital-lp.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.